Access cutting-edge myelofibrosis treatment through this clinical trial at a research site in Rochester. Study-provided care at no cost to qualified participants.
Access myelofibrosis specialists in Rochester at no cost
This study follows strict safety protocols and ethical guidelines
All study-related myelofibrosis treatment provided free
This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis (Cohorts 1-3) or Indolent Systemic Mastocytosis (Cohort 5). Participants must be diagnosed with Myelofibrosis and be relapsed/refractory (e.g., having failed prior therapy), intolerant, or ineligible to receive JAKi treatment, or be diagnosed with Indolent Systemic Mastocytosis.
Sponsor: Telios Pharma, Inc.
Check if you qualify for this myelofibrosis clinical trial in Rochester, MN
If you're searching for myelofibrosis treatment options in Rochester, MN, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Rochester research site is actively enrolling participants for this clinical trial. You'll receive care from experienced myelofibrosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.